Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sandeep Jani

Advanced Heart Failure and Transplant Cardiology Baltimore, MD Medical Doctor

NPI 1750549333 CMS profile 1039882

9105 Franklin Square Dr, Suite 209, Baltimore, MD 21237

Open in the dashboard

General payments

$75,400

119 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$265,341 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Sandeep Jani of Baltimore, MD is reported in the CMS Open Payments database as having received $75,400 across 119 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $265,341 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 83rd percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,553 17
2024 General $3,486 18
2023 General $21,999 37
2022 General $21,646 18
2021 General $5,194 9
2020 General $710 3
2019 General $7,812 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sandeep Jani
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Sandeep Jani were reported at $14,553. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Sandeep Jani Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $7,812 $863 $224–$4,562 $163
2020 $710 $452 $122–$3,992 $114
2021 $5,194 $550 $159–$3,571 $132
2022 $21,646 $729 $221–$4,357 $149
2023 $21,999 $1,002 $309–$5,827 $160
2024 $3,486 $931 $273–$5,204 $164
2025 $14,553 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $55,711 58 payments
  2. Pfizer Inc. $14,043 17 payments
  3. BridgeBio Pharma, Inc. $2,186 3 payments
  4. Akcea Therapeutics, Inc. $2,183 5 payments
  5. Abbott Laboratories $401 5 payments
  6. Abiomed $194 2 payments
  7. Novartis Pharmaceuticals Corporation $128 5 payments
  8. United Therapeutics Corporation $113 4 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $75 5 payments
  10. Medtronic Vascular, Inc. $66 2 payments
  11. Other $300 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $66,035 21 payments
  2. Food and Beverage $3,593 81 payments
  3. Consulting Fee $2,676 4 payments
  4. Honoraria $2,000 1 payment
  5. Travel and Lodging $1,083 10 payments
  6. Education $13 2 payments
Products named General payments · program years 2019–2025
  1. CAMZYOS $55,384 55 payments
  2. VYNDAQEL $14,043 17 payments
  3. Attruby $2,186 3 payments
  4. TEGSEDI $2,183 5 payments
  5. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $382 4 payments
  6. Impella $194 2 payments
  7. LEQVIO $105 4 payments
  8. LifeVest $75 5 payments
  9. HeartWare HVAD $66 2 payments
  10. FARXIGA $63 3 payments
  11. Other $573 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

3,223

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$4,630,887

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

33.5%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 110 $3,123,366
Entresto Sacubitril/Valsartan Brand 364 $545,376
Jardiance Empagliflozin Brand 213 $295,953
Eliquis Apixaban Brand 182 $244,522
Camzyos Mavacamten Brand 27 $216,686
Farxiga Dapagliflozin Propanediol Brand 98 $110,909
Xarelto Rivaroxaban Brand 37 $59,538
Metoprolol Succinate Generic 285 $4,430
Amiodarone Hcl Generic 120 $3,791
Eplerenone Generic 36 $3,234

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$124,780

Medicare's payments for the services billed

Medicare patients

490

Average age 73

Services billed

1,755

243 women, 247 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 74%
Chronic kidney disease 57%
Atrial fibrillation 56%
Diabetes 54%
Arthritis 49%
COPD 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $3,116
$3,116 27 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $55
$55 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $23
$23 98 —
XARELTO
  • Janssen Pharmaceuticals, Inc $18
$18 37 —
ORENITRAM
  • United Therapeutics Corporation $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record